Trial Profile
A Phase III Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an ART Regimen, Including TMC114/RTV and an Investigator-Selected OBR, in HIV-1 Infected Patients With Limited Treatment to No Treatment Options
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Etravirine (Primary) ; Darunavir; Ritonavir
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms DUET-2
- Sponsors Janssen R&D Ireland
- 27 Aug 2010 Pooled 96-week tolerability results from DUET-1 and DUET-2 have been published in the Journal of Antimicrobial Chemotherapy.
- 01 Jan 2010 Pooled 96-week efficacy and tolerability results from DUET-1 and DUET-2 have been published in Antiviral Therapy.
- 11 Nov 2009 Pooled 96-week tolerability results from DUET-1 and -2 were presented at EACS 2009.